Japanese drug makers reported mixed fiscal first-quarter earnings, with Takeda Pharmaceutical posting 18% growth in net profit on sales of new treatments while rival Daiichi Sankyo saw a 24% profit drop on the weak performance of its Indian unit.
Baxter & Baxter, LLP
Consumer Protection | Bankruptcy Attorneys | Oregon & Washington
